CartiHeal Receives FDA "Breakthrough Device Designation" for the novel Agili-C Implant
Tuesday, October 20, 2020
Breakthrough Designation Allows Expedited Review
KFAR SABA, Israel, Oct. 12, 2020 /PRNewswire/ -- CartiHeal, developer of Agili-C(TM), a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today that FDA has granted Breakthrough Device Designation for the Agili-C implant(TM).
https://mma.prnewswire.com/media/451231/CartiHeal_Logo.jpg
FDA's Breakthrough Device Program is reserved for certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases or conditions. This program is intended to help patients receive more timely access to these medical devices by expediting their development, assessment and review by FDA.
CartiHeal is currently conducting a pivotal IDE clinical study which is designed to evaluate the Agili-C(TM) implant superiority over the current surgical standard of care - microfracture and debridement. In total 251 Subjects were enrolled in 26 sites in the US, Europe and Israel. The study includes Subjects with both mild to moderate osteoarthritis and focal defects, without arthritic changes. Final study results are expected next year.
"We are extremely pleased that FDA granted the Agili-C implant Breakthrough Device Designation," said Nir Altschuler, CartiHeal's Founder & CEO. "We look forward to working closely with FDA to expedite Agili-C's review process, once the final IDE study results will be available, in order to provide a promising treatment for millions of patients who suffer from cartilage defects and currently lack good treatment options."
About CartiHeal
CartiHeal, a privately-held medical device company headquartered in Israel and New Jersey, develops proprietary implants for the treatment of cartilage and osteochondral defects in traumatic and osteoarthritic joints.
CartiHeal's cell-free, off-the-shelf implant is CE marked for use in cartilage and osteochondral defects. Agili-C(TM) has been implanted in over 500 study patients with knee, ankle, and great toe cartilage lesions in a series of clinical trials at leading centers in Europe and Israel - treating a broad spectrum of cartilage lesions, from single focal lesions to multiple and large defects in osteoarthritic patients.
In the United States, the Agili-C(TM) implant is not available for sale - it is an investigational device limited to use in the IDE clinical study.
For more information: www.cartiheal.com
info@cartiheal.com
Logo - https://mma.prnewswire.com/media/451231/CartiHeal_Logo.jpg
View original content:http://www.prnewswire.com/news-releases/cartiheal-receives-fda-breakthrough-device-designation-for-the-novel-agili-c-implant-301150023.html
SOURCE CartiHeal
|
|
|
|
|
 |
Asetek - Mandatory Notification of Trade | Jan 22, 2026
|
|
BC.GAME to Host "Stay Untamed" Night During Abu Dhabi's Packed Web3 Summit Week | Jan 22, 2026
|
|
Tomorrowland Brings the Magic to Shanghai for a Spectacular First Indoor Edition in China | Jan 22, 2026
|
|
Auburn University's Applied Research Institute Expands Advanced Manufacturing Capabilities with CF3D Enterprise Cell | Jan 22, 2026
|
|
Rent Manager Earned Best Real Estate Software Product Award and Multiple Review Badges from G2 Platform | Jan 22, 2026
|
|
California Divorce Mediation Center Unveils Modern Website Redesign | Jan 22, 2026
|
|
AMPERA ANNOUNCES LOCATION FOR GLOBAL HEADQUARTERS | Jan 22, 2026
|
|
Culture and tourism sectors thrive in Xiamen | Jan 22, 2026
|
|
Immutable Announces First Co-Founder-Hosted Live Webinar: How to Dominate Your Steam Launch | Jan 22, 2026
|
|
StackGen Named in Four Gartner® Hype Cycles(TM) for Platform Engineering, Infrastructure Strategy, Site Reliability Engineering, and I&O Automation in 2025 | Jan 22, 2026
|
|
|
